<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02327273</url>
  </required_header>
  <id_info>
    <org_study_id>MB006-002</org_study_id>
    <nct_id>NCT02327273</nct_id>
  </id_info>
  <brief_title>Randomized, Placebo-Controlled, Double-Blind, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-963272 in Healthy Subjects</brief_title>
  <official_title>Randomized, Placebo-Controlled, Double-Blind, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-963272 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety profile, tolerability, Pharmacokinetics
      (PK) and Pharmacodynamics (PD) following single and multiple oral doses of BMS-963272 in
      healthy subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Classification: Safety, PK/PD
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of single oral dose of BMS-963272 in healthy overweight and obese subjects is measured by adverse events, Serious adverse events, vital signs, laboratory assessments and ECG</measure>
    <time_frame>Up to 10 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of multiple oral doses of BMS-963272 in healthy overweight and obese subjects is measured by adverse events, Serious adverse events, vital signs, laboratory assessments and ECG</measure>
    <time_frame>With in 18 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Part A SAD: BMS-963272 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-963272 or Placebo oral capsule on specific days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B MAD: BMS-963272 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-963272 or Placebo oral capsule on specific days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-963272</intervention_name>
    <arm_group_label>Part A SAD: BMS-963272 or Placebo</arm_group_label>
    <arm_group_label>Part B MAD: BMS-963272 or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Part A SAD: BMS-963272 or Placebo</arm_group_label>
    <arm_group_label>Part B MAD: BMS-963272 or Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Healthy subjects as determined by no clinically significant deviation from normal in
             medical history, physical examination, ECGs and clinical laboratory determinations

          -  Body Mass Index (BMI) of 27 to 40 kg/m2 inclusive. BMI = weight (kg)/ [height (m)]2

          -  Females (not of childbearing potential and males, ages 18 to 55 years, inclusive.
             Female subjects must have documented proof that they are not of childbearing potential

          -  Azoospermic males and women who are not of child-bearing potential (i.e. are
             postmenopausal or surgically sterile; see section 3.3.3 for the definition of WOCBP)
             are exempt from contraceptive requirements. However, women must still undergo
             pregnancy testing as described in this section

        Exclusion Criteria:

          -  Evidence of organ dysfunction or any clinically significant deviation from normal in
             physical examination, vital signs, ECG or clinical laboratory determinations beyond
             what is consistent with the target population

          -  Any of the following on 12-lead electrocardiogram (ECG) prior to study drug
             administration, confirmed by repeat.

             i)PR ≥ 210 msec ii)QRS ≥ 120 msec iii)QT ≥ 500 msec iv)QTcF ≥ 450 msec

          -  Positive urine screen for drugs of abuse

          -  Positive blood screen for hepatitis C antibody, hepatitis B surface antigen, or HIV-1,
             -2 antibody

          -  Moderate anemia (hemoglobin &lt; 11 g/dL for men and &lt; 10 g/dL for women)

          -  aspartate aminotransferase (AST) &gt; 1.3x ULN

          -  alanine aminotransferase (ALT) &gt; 1.3x ULN

          -  Total bilirubin &gt; 1.3x upper limit of normal (ULN)

          -  estimated glomerular filtration rate (eGFR) &lt; 90 ml/min/1.73 m2 (calculated using
             CKD-EPI formula)

          -  HbA1c &gt; 6.5%

          -  Fasting total cholesterol &gt; 300 mg/dl

          -  Fasting triglycerides &gt; 400 mg/dl

          -  Systolic blood pressure &gt; 160 mm Hg and/or diastolic blood pressure &gt; 95 mm Hg,
             confirmed by repeat measurement

          -  History of any significant drug allergy (such as anaphylaxis or hepatotoxicity).

          -  History of lactose intolerance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ppd Development, Lp</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 24, 2014</study_first_submitted>
  <study_first_submitted_qc>December 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2014</study_first_posted>
  <last_update_submitted>July 21, 2015</last_update_submitted>
  <last_update_submitted_qc>July 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>subjects</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

